H.C. Wainwright initiated coverage of Dyne Therapeutics with a Buy rating and $36 price target. Dyne’s Force platform is what differentiates the company in the space that is looking to target one of the most notorious tissues in humans for anti-sense oligo based therapies-muscles, the analyst tells investors in a research note. The firm believes the ability to target TfR1 using Fab allows for greater enrichment of the oligo or SiRNA inside the muscle tissue, without the baggage of bulky monoclonal antibodies, receptor saturation, and loss, and rapid clearance of the drug from the blood and kidney.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
- Dyne Therapeutics to Present at February Investor Conferences
- Dyne Therapeutics resumes trading, up 29% after report of takeover interest
- Dyne Therapeutics trading resumes
- Dyne Therapeutics seeing takeover interest, weighing options, Bloomberg says